Publications by authors named "Chunfan Li"
Article Synopsis
- - Ibrutinib shows variable effectiveness in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with complete response rates ranging from 15% to 90% depending on the treatment regimen used.
- - When comparing treatment types, ibrutinib combination therapy has a higher complete remission rate (45%) compared to monotherapy (19%), but the overall survival rates for both treatments are similar, suggesting combination therapy primarily serves as a temporary measure before other treatments.
- - Overall, ibrutinib is generally safe and effective for R/R DLBCL, with tolerable side effects, although some patients experience significant adverse reactions, especially with combination therapy.
Metagenomic next-generation sequencing to diagnose atypical severe scrub typhus.
J Microbiol Immunol Infect
June 2022